Report describes shortfalls in mpox vaccination coverage among eligible persons in the US

A report describes shortfalls in mpox vaccination coverage among vaccine-eligible persons in the United States. The publication type is listed as a report, and no specific study type, phase, or design details were provided. The population of interest was vaccine-eligible persons, but the sample size was not reported. No specific intervention, exposure, or comparator was described.

The main finding was that shortfalls in mpox vaccination were described. No effect size, absolute numbers, p-values, confidence intervals, or direction of association were reported. The report did not specify primary or secondary outcomes. Follow-up duration was also not reported.

No safety or tolerability data on adverse events, serious adverse events, or discontinuations were provided. The report did not list specific limitations, and funding or conflicts of interest were not reported. The practice relevance and notes on causality or certainty were not specified. This is a descriptive report with limited quantitative data, making it difficult to assess the scope or specific causes of the vaccination coverage shortfalls.